Published in Neurology on May 24, 2005
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci (2009) 2.29
Olfactory dysfunction in Parkinson disease. Nat Rev Neurol (2012) 1.73
Association of anosmia with autonomic failure in Parkinson disease. Neurology (2010) 1.72
Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology (2011) 1.57
Olfaction in Parkinson's disease and related disorders. Neurobiol Dis (2011) 1.51
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord (2008) 1.49
Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett (2008) 1.08
Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord (2009) 1.08
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol (2007) 1.04
Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson's disease patients. Stereotact Funct Neurosurg (2008) 0.97
Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. Mov Disord (2010) 0.96
Odor identification and progression of parkinsonian signs in older persons. Exp Aging Res (2008) 0.88
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.85
PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev (2014) 0.82
The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. BMC Neurol (2011) 0.81
The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol (2010) 0.80
Current status of biomarker research in neurology. EPMA J (2016) 0.79
Taste function in early stage treated and untreated Parkinson's disease. J Neurol (2014) 0.78
Olfactory impairment in the rotenone model of Parkinson's disease is associated with bulbar dopaminergic D2 activity after REM sleep deprivation. Front Cell Neurosci (2014) 0.78
Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression. Behav Neurol (2015) 0.78
Suprathreshold odor intensity perception in early-stage Parkinson's disease. Mov Disord (2014) 0.77
Early diagnosis of Parkinson's disease. J Neurol (2006) 0.76
Nanomedicine in otorhinolaryngology: what does the future hold? Eur Arch Otorhinolaryngol (2010) 0.76
The Olfactory System Revealed: Non-Invasive Mapping by using Constrained Spherical Deconvolution Tractography in Healthy Humans. Front Neuroanat (2017) 0.75
Segmentation of the striatum from MR brain images to calculate the 99mTc-TRODAT-1 binding ratio in SPECT images. Comput Math Methods Med (2013) 0.75
Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinson's disease. Sci Rep (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol (1987) 8.48
Limbic activation during cue-induced cocaine craving. Am J Psychiatry (1999) 6.66
Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav (1984) 6.50
Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care. Lancet (1997) 6.41
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry (1991) 3.88
University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope (1984) 3.80
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology (2009) 3.65
Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J Psychiatry (2000) 3.49
Controlled trials in the evaluation of counselling in general practice. Br J Gen Pract (1994) 3.34
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 3.32
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med (2001) 3.24
Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry (1998) 3.02
Smell identification ability: changes with age. Science (1984) 2.87
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Prescribing and referral in general practice: a study of patients' expectations and doctors' actions. Br J Gen Pract (1994) 2.77
Computerized neurocognitive scanning: I. Methodology and validation in healthy people. Neuropsychopharmacology (2001) 2.70
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N Engl J Med (1971) 2.62
The impact of depressive symptoms in early Parkinson disease. Neurology (2007) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otolaryngol Head Neck Surg (1991) 2.34
Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol (1998) 2.29
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry (1994) 2.27
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Allergic alveolitis in a maltworker. Thorax (1968) 2.21
A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders. BMJ (1998) 2.14
The economics of employing a counsellor in general practice: analysis of data from a randomised controlled trial. Br J Gen Pract (2000) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09
Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry (1998) 2.09
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology (2001) 1.97
Defensive medicine and obstetrics. JAMA (1995) 1.97
Dose-related effects of cigarette smoking on olfactory function. JAMA (1990) 1.94
Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. Proc Natl Acad Sci U S A (1991) 1.91
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Biomarkers for early detection of Alzheimer pathology. Neurosignals (2007) 1.86
Sex differences in regional cerebral glucose metabolism during a resting state. Science (1995) 1.86
Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull (1987) 1.79
Immunity to primary and challenge infections of Trichinella spiralis in mice: a re-examination of conventional parameters. Parasitology (1976) 1.78
Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology (1991) 1.78
An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol (2006) 1.77
Non-attendance at psychiatric outpatient clinics: communication and implications for primary care. Br J Gen Pract (1999) 1.76
Olfactory identification deficits in schizophrenia: correlation with duration of illness. Am J Psychiatry (1997) 1.71
Immunologic aspects of human colostrum and milk. III. Fate and absorption of cellular and soluble components in the gastrointestinal tract of the newborn. J Immunol (1977) 1.69
Intranasal trigeminal stimulation from odorous volatiles: psychometric responses from anosmic and normal humans. Physiol Behav (1978) 1.69
Relations among clinical scales in schizophrenia. Am J Psychiatry (1991) 1.65
Normative neuropsychological test performance: effects of age, education, gender and ethnicity. Appl Neuropsychol (1995) 1.64
Community care reforms: early implications for general practice. Br J Gen Pract (1994) 1.63
Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol (2000) 1.63
Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test. Percept Psychophys (1989) 1.63
Spine radiographs in patients with low-back pain. An epidemiological study in men. J Bone Joint Surg Am (1984) 1.60
Promoting clinically effective practice: general practitioners' awareness of sources of research evidence. Fam Pract (1997) 1.60
Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology (2007) 1.59
Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res (1999) 1.58
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Allergic alveolitis in maltworkers. A clinical, mycological, and immunological study. Q J Med (1969) 1.57
Sex differences in odor identification ability: a cross-cultural analysis. Neuropsychologia (1985) 1.55
Ventricle-brain ratio, computed tomographic density, and brain area in 50 schizophrenics. Arch Gen Psychiatry (1989) 1.54
Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry (2001) 1.53
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol (2000) 1.52
Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Neuropsychopharmacology (1999) 1.50
Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1992) 1.50
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol (2000) 1.50
A review of olfactory dysfunctions in man. Am J Otolaryngol (1979) 1.49
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology (2008) 1.48
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
Complete rescue of photoreceptor dysplasia and degeneration in transgenic retinal degeneration slow (rds) mice. Neuron (1992) 1.40
[Screening of cervical cancer, false negative vaginal smears]. Rev Med Suisse Romande (1997) 1.39
Exercise after myocardial infarction: a controlled trial. J R Coll Physicians Lond (1982) 1.37
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
Purification and characterization of two initiation factors required for maximal activity of a highly fractionated globin mRNA translation system. Proc Natl Acad Sci U S A (1976) 1.36
Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry (1995) 1.34
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology (2007) 1.33
Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther (2001) 1.30
F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med (2001) 1.28
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology (2004) 1.28
Self-rated economic condition and the health of elderly persons in Hong Kong. Soc Sci Med (2002) 1.27
Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technol Assess (2000) 1.27
Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology (1989) 1.27
Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol (1983) 1.25
"Locked-in" state with bilateral midbrain infarcts. Arch Neurol (1974) 1.24
Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol (1991) 1.24
Kallmann syndrome: MR evaluation of olfactory system. AJNR Am J Neuroradiol (1993) 1.24